Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCR-AUD in healthy volunteers
NCT05845398Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Primary completion
- Aug 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alcohol use disorder (AUD) comparing DCR-AUD with Placebo (2 arms). Primary endpoints: Treatment-emergent Adverse Events at 24 weeks, Severity Grades of Treatment-emergent Adverse Events at 24 weeks and 4 more. Started Jan 2023; status: completed.
02
Drugs
DCR-AUD
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05845398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845398.